Gemtuzumab
Gemtuzumab Ozogamicin
Gemtuzumab Ozogamicin (pronounced as gem-too-zoo-mab oh-zoh-ga-mye-sin) is a monoclonal antibody used in the treatment of acute myeloid leukemia (AML). It is marketed under the brand name Mylotarg.
Etymology
The name Gemtuzumab is derived from Gem referring to gemtuzumab, the humanized monoclonal antibody, and tuzumab is a stem used for humanized antibodies. Ozogamicin refers to the cytotoxic agent that the antibody is linked to.
Usage
Gemtuzumab Ozogamicin is used to treat patients with CD33-positive AML. It is a CD33 directed antibody and calicheamicin conjugate. The drug binds to the CD33 antigen, which is expressed on the surface of leukemic blasts in most patients with AML, leading to DNA damage and cell death.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Acute myeloid leukemia (AML): A type of cancer that affects the blood and bone marrow.
- CD33: A transmembrane receptor expressed on cells of myeloid lineage that is used as a target for certain cancer therapies.
- Calicheamicin: A type of enediyne antitumor antibiotic that is used as a cytotoxic agent in certain cancer treatments.
Side Effects
Common side effects of Gemtuzumab Ozogamicin include fever, nausea, infection, vomiting, bleeding, low blood cell counts, and fatigue. Severe side effects may include liver problems, infusion reactions, and low blood cell counts.
External links
- Medical encyclopedia article on Gemtuzumab
- Wikipedia's article - Gemtuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski